MM Patients May Benefit From Surgery, Regardless of Lesion Location
Preoperative pain, prothrombin time activity (PTA), albumin, urine protein, and postoperative chemotherapy appeared to be associated with prognosis.
OS Boost With Quizartinib in R/R AML
This study is the first to show significantly improved OS from single-agent treatment in this particularly difficult to treat population.
Nivolumab Is China’s First Approved Immuno-Oncology Drug
In CheckMate -078, nivolumab yielded superior OS compared with docetaxel in previously treated NSCLC, regardless of PD-L1 expression and tumor histology.
Role for PET Imaging in Reducing Tx Toxicity in Advanced Hodgkin Lymphoma?
De-escalated treatment may be possible in patients with advanced HL who reach a metabolic response after only 2 cycles of escalated BEACOPP.
Lenalidomide/Rituximab Combo Effective in Advanced FL
Efficacy of lenalidomide plus rituximab was similar to chemotherapy induction in previously untreated symptomatic FL, with a better safety profile.
Higher Indel Counts Linked to Improved OS in RCC
In RCC patients on anti–PD-1 therapy, besides the indel count link to better OS, baseline tumor infiltration with M2 macrophages predicted improved PFS.
CVD Risk Factors Identified in Male Thyroid Cancer Survivors
In the Utah Cancer Survivors Study, male thyroid cancer survivors had an almost 50% higher risk of developing cardiovascular disease than females.
Will Large Gene Study Help to Personalize Thyroid Cancer Tx?
The study is potentially a “leap forward” in cancer genomics, particularly for subsets of patients with metastatic and anaplastic thyroid cancer.
Ra-223 Dichloride in mCRPC: More Is Not Better
A multicenter, international phase II study found higher-dose and extended-dose therapy with Ra-223 did not improve survival or pain scores.
In DLBCL, Polatuzumab Combo Yields ‘Marked Improvement’ in CR, PFS, OS
Polatuzumab vedotin administered with bendamustine and rituximab significantly improved PET-based CR rates, PFS, and OS in DLBCL but not FL.
Adjuvant Denosumab Fails to Reduce Recurrences, Deaths in Early Breast Cancer
The D-CARE study found adjuvant denosumab is devoid of benefits in high-risk early breast cancer.
Second-Line Irinotecan/Cetuximab/Ramucirumab Combo Ups PFS in Advanced CRC
A combination of irinotecan, cetuximab, and ramucirumab may boost PFS in advanced CRC, when given after failure of oxaliplatin-and-bevacizumab–based therapy.
Altering Gut Microbiome May Improve ICI Outcomes in RCC
Making some changes to the gut microbiome may improve outcomes with immune checkpoint inhibitors in renal cell carcinoma.
Sorafenib Did Not Improve RFS in mRCC After Radical Resection
In the Italian RESORT trial, sorafenib did not affect recurrence-free survival in patients with mRCC following radical resection of metastases.
Durable Responses in R/R DLBCL With CAR-T Product Lisocabtagene Maraleucel
In TRANSCEND NHL 001, the CD19-directed 4-1BB CAR T-cell product lisocabtagene maraleucel yielded durable responses in heavily pretreated R/R DLBCL.
Pembrolizumab Bests Chemotherapy in PD-L1–Expressing NSCLC
Pembrolizumab represents a new standard first-line treatment option for PD-L1–expressing advanced/metastatic NSCLC, according to KEYNOTE-042 investigators.
Personalized Molecular Phenotyping May Help Secondary AML
This approach may lead to better understanding of risk-mitigation strategies, and perhaps better outcomes in patients with secondary AML.
Unconventional Strategies May Be Required for TP53-Mutated AML
Unconventional strategies and targeted therapeutics may be required to overcome the adverse risks associated with TP53-mutated AML.
Gender Disparities in Head and Neck Cancer Treatment?
A California study showed women are significantly undertreated for head and neck cancer, with several factors possibly accounting for the disparity.
Geriatric Assessment Summaries May Benefit Oncologists
The use of geriatric assessment in routine care of older patients with advanced cancer may significantly improve doctor-patient communication.
Cellular Therapies for Multiple Myeloma: A Paradigm Shift
Therapy with CAR T cells may benefit patients with highly refractory multiple myeloma, said U Penn’s Adam Cohen at ASCO 2018.
Genomics Revolution Taking Off in Multiple Myeloma
Risk stratification is leading to increasing numbers of new molecular targets in multiple myeloma.
Smart Technology May Improve Head and Neck Cancer Care
In a CYCORE trial, mobile technology improved patient tracking, enabling clinicians to detect concerning symptoms early and respond quicker.
Dabrafenib/Trametinib Approved for BRAF-Positive Anaplastic Thyroid Cancer
The approval should have a profound impact on patients with the rare tumor, according to experts.
Salvage Cryoablation May Delay the Need for Hormone Therapy in Recurrent Prostate Cancer
Salvage cryoablation following local recurrence post radiation may be a safe way to avoid or delay initiation of hormone deprivation therapy.
PROSPER: Enzalutamide Benefit in Nonmetastatic CRPC?
A new analysis of PROSPER, presented at AUA 2018, suggests enzalutamide plus ADT may be superior to ADT alone in nonmetastatic CRPC.
CBT, Acupuncture Combat Insomnia in Cancer Survivors
A study led by Dr. Jun Mao of MSKCC found CBT and acupuncture each yielded clinically meaningful and durable sleep-related QOL improvements.
Sarcopenia Predicts Tumor Recurrence Post Liver Transplantation?
Recurrence risk was greater in sarcopenic patients, and greater alpha-fetoprotein and microvascular invasion were independent risk factors.
Mathematical Modeling May Guide Cancer Treatment 'Holidays'
A Moffitt team suggests mathematical modeling may guide the optimal cancer treatment dosing approach better than MTD.
RCC Agent Lenvatinib of Benefit in Anaplastic Thyroid Cancer
Certain genetic alterations associated with anaplastic transformation in thyroid cancer made patients sensitive to the multikinase inhibitor lenvatinib.